Gene therapy in epilepsy

The focus on NPY

Francesco Noe', Jari Nissinen, Asla Pitkänen, Marco Gobbi, Gunther Sperk, Matthew During, Annamaria Vezzani

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Gene therapy represents an innovative and promising alternative for the treatment of epileptic patients who are resistant to conventional antiepileptic drugs. Among the various approaches for the application of gene therapy in the treatment of CNS disorders, recombinant viral vectors have been most widely used so far. Several gene targets could be used to correct the compromized balance between inhibitory and excitatory transmission in epilepsy. Transduction of neuropeptide genes such as galanin and neuropeptide Y (NPY) in specific brain areas in experimental models of seizures resulted in significant anticonvulsant effects. In particular, the long-lasting NPY over-expression obtained in the rat hippocampus using intracerebral application of recombinant adeno-associated viral (AAV) vectors reduced the generalization of seizures from their site of onset, delayed acquisition of fully kindled seizures and afforded neuroprotection. These results establish a proof-of-principle for the applicability of AAV-NPY vectors for the inhibition of seizures in epilepsy. Additional investigations are required to demonstrate a therapeutic role of gene therapy in chronic models of seizures and to address in more detail safety concerns and possible side-effects.

Original languageEnglish
Pages (from-to)377-383
Number of pages7
JournalPeptides
Volume28
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Gene therapy
Neuropeptide Y
Genetic Therapy
Epilepsy
Seizures
Anticonvulsants
Genes
Galanin
Neuropeptides
Rats
Brain
Hippocampus
Theoretical Models
Therapeutics
Safety

Keywords

  • Adeno-associated viral vectors
  • Drug resistance
  • Experimental models of seizures
  • Hippocampus

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Noe', F., Nissinen, J., Pitkänen, A., Gobbi, M., Sperk, G., During, M., & Vezzani, A. (2007). Gene therapy in epilepsy: The focus on NPY. Peptides, 28(2), 377-383. https://doi.org/10.1016/j.peptides.2006.07.025

Gene therapy in epilepsy : The focus on NPY. / Noe', Francesco; Nissinen, Jari; Pitkänen, Asla; Gobbi, Marco; Sperk, Gunther; During, Matthew; Vezzani, Annamaria.

In: Peptides, Vol. 28, No. 2, 02.2007, p. 377-383.

Research output: Contribution to journalArticle

Noe', F, Nissinen, J, Pitkänen, A, Gobbi, M, Sperk, G, During, M & Vezzani, A 2007, 'Gene therapy in epilepsy: The focus on NPY', Peptides, vol. 28, no. 2, pp. 377-383. https://doi.org/10.1016/j.peptides.2006.07.025
Noe' F, Nissinen J, Pitkänen A, Gobbi M, Sperk G, During M et al. Gene therapy in epilepsy: The focus on NPY. Peptides. 2007 Feb;28(2):377-383. https://doi.org/10.1016/j.peptides.2006.07.025
Noe', Francesco ; Nissinen, Jari ; Pitkänen, Asla ; Gobbi, Marco ; Sperk, Gunther ; During, Matthew ; Vezzani, Annamaria. / Gene therapy in epilepsy : The focus on NPY. In: Peptides. 2007 ; Vol. 28, No. 2. pp. 377-383.
@article{5058ef9f1cb44a369a0bc45aef99fa75,
title = "Gene therapy in epilepsy: The focus on NPY",
abstract = "Gene therapy represents an innovative and promising alternative for the treatment of epileptic patients who are resistant to conventional antiepileptic drugs. Among the various approaches for the application of gene therapy in the treatment of CNS disorders, recombinant viral vectors have been most widely used so far. Several gene targets could be used to correct the compromized balance between inhibitory and excitatory transmission in epilepsy. Transduction of neuropeptide genes such as galanin and neuropeptide Y (NPY) in specific brain areas in experimental models of seizures resulted in significant anticonvulsant effects. In particular, the long-lasting NPY over-expression obtained in the rat hippocampus using intracerebral application of recombinant adeno-associated viral (AAV) vectors reduced the generalization of seizures from their site of onset, delayed acquisition of fully kindled seizures and afforded neuroprotection. These results establish a proof-of-principle for the applicability of AAV-NPY vectors for the inhibition of seizures in epilepsy. Additional investigations are required to demonstrate a therapeutic role of gene therapy in chronic models of seizures and to address in more detail safety concerns and possible side-effects.",
keywords = "Adeno-associated viral vectors, Drug resistance, Experimental models of seizures, Hippocampus",
author = "Francesco Noe' and Jari Nissinen and Asla Pitk{\"a}nen and Marco Gobbi and Gunther Sperk and Matthew During and Annamaria Vezzani",
year = "2007",
month = "2",
doi = "10.1016/j.peptides.2006.07.025",
language = "English",
volume = "28",
pages = "377--383",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Gene therapy in epilepsy

T2 - The focus on NPY

AU - Noe', Francesco

AU - Nissinen, Jari

AU - Pitkänen, Asla

AU - Gobbi, Marco

AU - Sperk, Gunther

AU - During, Matthew

AU - Vezzani, Annamaria

PY - 2007/2

Y1 - 2007/2

N2 - Gene therapy represents an innovative and promising alternative for the treatment of epileptic patients who are resistant to conventional antiepileptic drugs. Among the various approaches for the application of gene therapy in the treatment of CNS disorders, recombinant viral vectors have been most widely used so far. Several gene targets could be used to correct the compromized balance between inhibitory and excitatory transmission in epilepsy. Transduction of neuropeptide genes such as galanin and neuropeptide Y (NPY) in specific brain areas in experimental models of seizures resulted in significant anticonvulsant effects. In particular, the long-lasting NPY over-expression obtained in the rat hippocampus using intracerebral application of recombinant adeno-associated viral (AAV) vectors reduced the generalization of seizures from their site of onset, delayed acquisition of fully kindled seizures and afforded neuroprotection. These results establish a proof-of-principle for the applicability of AAV-NPY vectors for the inhibition of seizures in epilepsy. Additional investigations are required to demonstrate a therapeutic role of gene therapy in chronic models of seizures and to address in more detail safety concerns and possible side-effects.

AB - Gene therapy represents an innovative and promising alternative for the treatment of epileptic patients who are resistant to conventional antiepileptic drugs. Among the various approaches for the application of gene therapy in the treatment of CNS disorders, recombinant viral vectors have been most widely used so far. Several gene targets could be used to correct the compromized balance between inhibitory and excitatory transmission in epilepsy. Transduction of neuropeptide genes such as galanin and neuropeptide Y (NPY) in specific brain areas in experimental models of seizures resulted in significant anticonvulsant effects. In particular, the long-lasting NPY over-expression obtained in the rat hippocampus using intracerebral application of recombinant adeno-associated viral (AAV) vectors reduced the generalization of seizures from their site of onset, delayed acquisition of fully kindled seizures and afforded neuroprotection. These results establish a proof-of-principle for the applicability of AAV-NPY vectors for the inhibition of seizures in epilepsy. Additional investigations are required to demonstrate a therapeutic role of gene therapy in chronic models of seizures and to address in more detail safety concerns and possible side-effects.

KW - Adeno-associated viral vectors

KW - Drug resistance

KW - Experimental models of seizures

KW - Hippocampus

UR - http://www.scopus.com/inward/record.url?scp=33846604310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846604310&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2006.07.025

DO - 10.1016/j.peptides.2006.07.025

M3 - Article

VL - 28

SP - 377

EP - 383

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 2

ER -